Global Cervical Cancer Market Landscape Report 2021: AstraZeneca Leads Industry Sponsors & Roche has the Highest Number of Completed Clinical Trials
June 15, 2021 05:08 ET
|
Research and Markets
Dublin, June 15, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Cervical Cancer" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the Cervical Cancer...
Global Cervical Cancer Market Report 2020: Insight, Epidemiology and Market Forecast 2017-2030 - Unmet Needs, Marketed Therapies, Emerging Therapies, Treatment and Management
December 08, 2020 03:18 ET
|
Research and Markets
Dublin, Dec. 08, 2020 (GLOBE NEWSWIRE) -- The "Cervical Cancer - Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. This...
Clinical Data Presented at ASCO Demonstrate Significant Overall Survival Benefit in rGBM Patients Receiving VB-111 Compared with Historical Avastin® Meta-analysis Data
June 03, 2016 16:02 ET
|
VBL Therapeutics
VBL's Phase 2 study in recurrent glioblastoma (rGBM) met the primary endpoint of statistically-significant increase in median overall survival, with 59 weeks in patients treated with continuous...
Cerulean Reports Third-Quarter 2014 Corporate Highlights and Financial Results
November 13, 2014 16:06 ET
|
Daré Bioscience, Inc.
CAMBRIDGE, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting™, today provided an update on corporate activities during the quarter...
Dr. Napoleone Ferrara Joins the New Scientific Advisory Board of Protelica Incorporated
September 10, 2013 06:30 ET
|
Protelica, Inc.
HAYWARD, Calif., Sept. 10, 2013 (GLOBE NEWSWIRE) -- Dr. Napoleone Ferrara, a world renowned authority on angiogenesis, and the developer of the anti-cancer drug Avastin has joined Protelica's newly...